Katelyn Mccabe Willis PhD, BA

Dr. Katelyn Willis is the Cell Biology Group Leader at Inhibrx. Prior to joining Inhibrx in 2014, Dr. Willis was a postdoctoral scholar at the Moores Cancer Center at UCSD, where she completed the Cancer Therapeutics Training (CT2) and Clinical Research Enhancement through Supplemental Training (CREST) programs. Her research focused on small molecule drug combinations for the treatment of ovarian cancer. Dr. Willis received her B.A. in Biology from Amherst College and her Ph.D. in Molecular and Medical Pharmacology from UCLA, where she designed and engineered antibodies for diagnostic and therapeutic applications.